Emerging roles of aerobic glycolysis in breast cancer

[1]  M. Farrar,et al.  JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors , 2019, Proceedings of the National Academy of Sciences.

[2]  G. Wong,et al.  Notch and mTOR Signaling Pathways Promote Human Gastric Cancer Cell Proliferation , 2019, Neoplasia.

[3]  Juan Li,et al.  Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer , 2019, Molecular Cancer.

[4]  Jieqing Li,et al.  AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer , 2019, Breast Cancer Research.

[5]  J. Onuchic,et al.  Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways , 2019, Proceedings of the National Academy of Sciences.

[6]  Qin Li,et al.  Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation , 2018, Cell Communication and Signaling.

[7]  Dou Liu,et al.  Metabolic regulation of T cell development by Sin1–mTORC2 is mediated by pyruvate kinase M2 , 2018, Journal of molecular cell biology.

[8]  J. Morrow,et al.  The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance , 2018, Nature Communications.

[9]  Xiaolong Yang,et al.  Targeting the Hippo Pathway for Breast Cancer Therapy , 2018, Cancers.

[10]  W. Guo,et al.  PKM2 promotes glucose metabolism through a let‐7a‐5p/Stat3/hnRNP‐A1 regulatory feedback loop in breast cancer cells , 2018, Journal of cellular biochemistry.

[11]  N. Zhang,et al.  Narciclasine induces autophagy‐dependent apoptosis in triple‐negative breast cancer cells by regulating the AMPK‐ULK1 axis , 2018, Cell proliferation.

[12]  Yonghong Sun,et al.  PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer , 2018, Oncogene.

[13]  L. Cantley,et al.  A Glycolysis Outsider Steps into the Cancer Spotlight. , 2018, Cell metabolism.

[14]  Shijun Lu,et al.  HSPC159 promotes proliferation and metastasis by inducing epithelial‐mesenchymal transition and activating the PI3K/Akt pathway in breast cancer , 2018, Cancer science.

[15]  Shu-yu Yang,et al.  Chibby suppresses aerobic glycolysis and proliferation of nasopharyngeal carcinoma via the Wnt/β-catenin-Lin28/let7-PDK1 cascade , 2018, Journal of Experimental & Clinical Cancer Research.

[16]  G. Mills,et al.  EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. , 2018, Molecular cell.

[17]  K. Rajapakshe,et al.  Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer , 2018, Nature.

[18]  Arash Salmaninejad,et al.  Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis , 2018, Cellular Oncology.

[19]  Prashant Kumar,et al.  AMPK-Akt Double-Negative Feedback Loop in Breast Cancer Cells Regulates Their Adaptation to Matrix Deprivation. , 2018, Cancer research.

[20]  Y. Li,et al.  Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. , 2018, Cancer cell.

[21]  Qiang Li,et al.  PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. , 2018, International journal of oncology.

[22]  S. Paul,et al.  Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2 , 2018, PloS one.

[23]  A. Fersht,et al.  Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. , 2018, Cancer letters.

[24]  K. Mcgregor,et al.  Global cancer control: responding to the growing burden, rising costs and inequalities in access , 2018, ESMO Open.

[25]  M. Wang,et al.  Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression , 2018, Technology in cancer research & treatment.

[26]  Jian-ying Zhang,et al.  IGF-1-mediated PKM2/β-catenin/miR-152 regulatory circuit in breast cancer , 2017, Scientific Reports.

[27]  Xiaoming Fan,et al.  Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death , 2017, British Journal of Cancer.

[28]  Darjus F. Tschaharganeh,et al.  Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. , 2017, Cancer research.

[29]  R. Kulshreshtha,et al.  P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer , 2017, RNA.

[30]  M. Toborek,et al.  Occludin regulates glucose uptake and ATP production in pericytes by influencing AMP-activated protein kinase activity , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  Pradip De,et al.  PI3K‐AKT‐mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials , 2017, Pharmacology & therapeutics.

[32]  N. Altorki,et al.  Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake , 2017, eLife.

[33]  N. Altorki,et al.  Author response: Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake , 2017 .

[34]  Y. Miao,et al.  MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer , 2017, Cell Death & Disease.

[35]  B. Shi,et al.  The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway , 2017, Oncology letters.

[36]  S. Ganapathy-Kanniappan,et al.  Taming Tumor Glycolysis and Potential Implications for Immunotherapy , 2017, Front. Oncol..

[37]  J. Portais,et al.  High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells , 2017, Leukemia.

[38]  S. Hare,et al.  mTOR function and therapeutic targeting in breast cancer. , 2017, American journal of cancer research.

[39]  Wei Zheng,et al.  MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway , 2017, Scientific Reports.

[40]  R. Hu,et al.  Gen‐27, a newly synthesized flavonoid, inhibits glycolysis and induces cell apoptosis via suppression of hexokinase II in human breast cancer cells , 2017, Biochemical pharmacology.

[41]  K. Mu,et al.  SHARPIN Facilitates p53 Degradation in Breast Cancer Cells12 , 2017, Neoplasia.

[42]  Xing Li,et al.  High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. , 2016, Breast.

[43]  A. Guerrero-Zotano,et al.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment , 2016, Cancer and Metastasis Reviews.

[44]  T. Jacks,et al.  PKM2, cancer metabolism, and the road ahead , 2016, EMBO reports.

[45]  Bin Wang,et al.  Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. , 2016, Clinical breast cancer.

[46]  J. Chesney,et al.  Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer , 2016, Breast Cancer Research and Treatment.

[47]  R. Fürst.  Narciclasine – an Amaryllidaceae Alkaloid with Potent Antitumor and Anti-Inflammatory Properties , 2016, Planta Medica.

[48]  I. Desideri,et al.  Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. , 2016, Cancer treatment reviews.

[49]  D. Thakker,et al.  Cation‐selective transporters are critical to the AMPK‐mediated antiproliferative effects of metformin in human breast cancer cells , 2016, International journal of cancer.

[50]  Shaoli Song,et al.  Interaction with Pyruvate Kinase M2 Destabilizes Tristetraprolin by Proteasome Degradation and Regulates Cell Proliferation in Breast Cancer , 2016, Scientific Reports.

[51]  T. Tsakiridis,et al.  Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. , 2016, Metabolism: clinical and experimental.

[52]  Tomasz S Tkaczyk,et al.  Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. , 2015, Cancer research.

[53]  G. Semenza,et al.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[54]  G. J. Yoshida.  Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of Experimental & Clinical Cancer Research.

[55]  F. Gu,et al.  High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer , 2015, Journal of Cancer.

[56]  Dario R. Roque,et al.  Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling. , 2015, Gynecologic oncology.

[57]  Hariniaina Rampanarivo,et al.  A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. , 2015, Journal of medicinal chemistry.

[58]  Yuanting Gu,et al.  Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. , 2015, Biochemical and biophysical research communications.

[59]  Jin Han,et al.  Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells , 2015, PloS one.

[60]  C. Dang,et al.  MYC and metabolism on the path to cancer. , 2015, Seminars in cell & developmental biology.

[61]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[62]  S. Miyamoto,et al.  HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection , 2015, Autophagy.

[63]  K. Komurov,et al.  HER2-mTOR signaling–driven breast cancer cells require ER-associated degradation to survive , 2015, Science Signaling.

[64]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Xiao-xin Sun,et al.  The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc , 2015, Proceedings of the National Academy of Sciences.

[66]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[67]  Z. Lu,et al.  Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression , 2015, Oncogene.

[68]  Jin-Ling Tang,et al.  The prognostic value of phosphorylated Akt in breast cancer: a systematic review , 2015, Scientific Reports.

[69]  Qing-hua Zhou,et al.  Review of aerobic glycolysis and its key enzymes – new targets for lung cancer therapy , 2015, Thoracic cancer.

[70]  A. Alonso,et al.  Loss of GLUT4 Induces Metabolic Reprogramming and Impairs Viability of Breast Cancer Cells , 2015, Journal of cellular physiology.

[71]  D. Hardie.  AMPK--sensing energy while talking to other signaling pathways. , 2014, Cell metabolism.

[72]  Roger L. Williams,et al.  The structural basis for mTOR function. , 2014, Seminars in cell & developmental biology.

[73]  Li-Ju Chang,et al.  Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. , 2014, Cell reports.

[74]  M. Askarian-Amiri,et al.  Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs , 2014, Front. Oncol..

[75]  A. Yalçin,et al.  6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27 , 2014, Cell Death and Disease.

[76]  M. Díaz-Zaragoza,et al.  Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). , 2014, Oncology reports.

[77]  Marc Coram,et al.  Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition , 2014, Breast Cancer Research.

[78]  K. Bottum,et al.  Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling. , 2014, Carcinogenesis.

[79]  P. Mischel,et al.  mTORC2 dictates Warburg effect and drug resistance , 2014, Cell cycle.

[80]  Michael N. Hall,et al.  Making new contacts: the mTOR network in metabolism and signalling crosstalk , 2014, Nature Reviews Molecular Cell Biology.

[81]  J. Montero,et al.  Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer , 2014, Oncogene.

[82]  Feng Liu,et al.  mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. , 2013, Cell metabolism.

[83]  S. Gygi,et al.  Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signaling to suppress tumorigenesis , 2013, Nature Cell Biology.

[84]  Takashi Suzuki,et al.  Hexokinase II in breast carcinoma: A potent prognostic factor associated with hypoxia‐inducible factor‐1α and Ki‐67 , 2013, Cancer science.

[85]  B. Manning,et al.  Signal integration by mTORC1 coordinates nutrient input with biosynthetic output , 2013, Nature Cell Biology.

[86]  B. Thorens,et al.  The SLC2 (GLUT) family of membrane transporters. , 2013, Molecular aspects of medicine.

[87]  A. Alonso,et al.  17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. , 2013, Endocrinology.

[88]  David Garcia-Dorado,et al.  Akt-dependent Activation of the Heart 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB2) Isoenzyme by Amino Acids* , 2013, The Journal of Biological Chemistry.

[89]  Hyunseung Lee,et al.  A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. , 2013, Cancer letters.

[90]  Hyunjin Shin,et al.  Estrogen receptor prevents p53-dependent apoptosis in breast cancer , 2012, Proceedings of the National Academy of Sciences.

[91]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[92]  Xinbin Chen,et al.  p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells* , 2012, The Journal of Biological Chemistry.

[93]  Yong Li,et al.  A novel miR‐155/miR‐143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells , 2012, The EMBO journal.

[94]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[95]  M. Birnbaum,et al.  PPARγ contributes to PKM2 and HK2 expression in fatty liver , 2012, Nature Communications.

[96]  T. Mak,et al.  PKM2: A gatekeeper between growth and survival , 2011, Cell Research.

[97]  P. Sorensen,et al.  The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis , 2011, Cell Death and Differentiation.

[98]  S. Fox,et al.  “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future? , 2011, Breast Cancer Research and Treatment.

[99]  Antonio Rosato,et al.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. , 2011, Cancer cell.

[100]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[101]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.

[102]  H. Gómez,et al.  The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer , 2010, Cancer and Metastasis Reviews.

[103]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[104]  Mélanie Schmidt,et al.  The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. , 2010, Anticancer research.

[105]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[106]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[107]  A. Krainer,et al.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism , 2010, Proceedings of the National Academy of Sciences.

[108]  Nadine Cybulski,et al.  TOR complex 2: a signaling pathway of its own. , 2009, Trends in biochemical sciences.

[109]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[110]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[111]  H. Thorne,et al.  BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression , 2009, British Journal of Cancer.

[112]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[113]  A. Lane,et al.  Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases* , 2009, The Journal of Biological Chemistry.

[114]  G. Das,et al.  Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy , 2009, Breast Cancer Research and Treatment.

[115]  Saroj P. Mathupala,et al.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.

[116]  T. Fleming,et al.  Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. , 2009, Cancer research.

[117]  A. Ridley,et al.  Phosphoinositide 3‐kinases in cell migration , 2009, Biology of the cell.

[118]  J. Rathmell,et al.  Glucose Metabolism Attenuates p53 and Puma-dependent Cell Death upon Growth Factor Deprivation* , 2008, Journal of Biological Chemistry.

[119]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[120]  D. Bentrem,et al.  Apigenin Inhibits the GLUT-1 Glucose Transporter and the Phosphoinositide 3-Kinase/Akt Pathway in Human Pancreatic Cancer Cells , 2008, Pancreas.

[121]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[122]  M. Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2008, Cell.

[123]  K. Inoki,et al.  Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling , 2008, The EMBO journal.

[124]  Nobuyuki Tanaka,et al.  p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.

[125]  A. Biankin,et al.  The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome , 2008, Breast Cancer Research.

[126]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[127]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[128]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[129]  M. Czech,et al.  The GLUT4 glucose transporter. , 2007, Cell metabolism.

[130]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[131]  Emmanuel Chamorey,et al.  HIF‐1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome , 2007 .

[132]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[133]  J. Simons,et al.  Hypoxia-inducible factor-1 in human breast and prostate cancer. , 2006, Endocrine-related cancer.

[134]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[135]  Kevin M. Ryan,et al.  DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis , 2006, Cell.

[136]  D. Green,et al.  p53 and Metabolism: Inside the TIGAR , 2006, Cell.

[137]  M. Carrasco,et al.  Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues , 2006, Journal of cellular physiology.

[138]  Ken Garber,et al.  Energy Deregulation: Licensing Tumors to Grow , 2006, Science.

[139]  Yong-Hwan Lee,et al.  Crystal Structure of the Hypoxia-inducible Form of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) , 2006, Journal of Biological Chemistry.

[140]  H. Esumi,et al.  Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. , 2005, Biochimie.

[141]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[142]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[143]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[144]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[145]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[146]  I. Bauerfeind,et al.  Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.

[147]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[148]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[149]  Yong-Koo Park,et al.  Clinical Significance of Glucose Transporter 1 (GLUT1) Expression in Human Breast Carcinoma , 2002, Japanese journal of cancer research : Gann.

[150]  Susan M. Kilroy,et al.  PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.

[151]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[152]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[153]  David Carling,et al.  Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). , 2002, Journal of cell science.

[154]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[155]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[156]  R. Wahl,et al.  Expression of hexokinase II and Glut-1 in untreated human breast cancer. , 2002, Nuclear medicine and biology.

[157]  H. Kung,et al.  Signaling network of the Btk family kinases , 2000, Oncogene.

[158]  D. Lombardo,et al.  Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. , 2000, Endocrinology.

[159]  D. Carling,et al.  Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia , 2000, Current Biology.

[160]  G. Shulman,et al.  Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. , 1999, The American journal of physiology.

[161]  R. Brown,et al.  GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. , 1995, Anticancer research.

[162]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[163]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[164]  H. Lodish,et al.  Liver glucose transporter: a basolateral protein in hepatocytes and intestine and kidney cells. , 1990, The American journal of physiology.

[165]  G I Bell,et al.  Sequence, tissue distribution, and chromosomal localization of mRNA encoding a human glucose transporter-like protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[166]  W. Criss.  A review of isozymes in cancer. , 1971, Cancer research.

[167]  B. Faubert,et al.  Myc induces expression of glutamine synthetase through promoter demethylation , 2015 .

[168]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[169]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[170]  V Clower Cynthia,et al.  選択的スプライシングレプレッサーhnRNP A1/A2とPTBはピルビン酸キナーゼアイソフォーム発現と細胞代謝に影響する , 2010 .

[171]  Jungho Kim,et al.  Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. , 2008, The international journal of biochemistry & cell biology.

[172]  Emmanuel Chamorey,et al.  HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. , 2007, International journal of cancer.

[173]  A. Rajasekaran,et al.  Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. , 2006, The Journal of biological chemistry.

[174]  S. Konduri,et al.  Estrogen Receptor- (cid:1) Binds p53 Tumor Suppressor Protein Directly and Represses Its Function , 2006 .

[175]  T. Seki,et al.  An Immunohistochemical Study , 2006 .

[176]  Richard J. Shaw.  Inaugural Article: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress , 2004 .

[177]  R. Bartrons,et al.  PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. , 2001, Trends in biochemical sciences.

[178]  J. Pessin,et al.  Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. , 1996, Annual review of nutrition.

[179]  B. V. van Oirschot,et al.  Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue. , 1987, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[180]  A. Azad,et al.  Estrogen receptor-directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. , 2022 .